Licorice is used as a medicinal plant, and several studies have shown that licorice has beneficial effects. The objective of this study was to evaluate the safety of nonpolar licorice extract using toxicity experiments. Nonpolar extract from the root of Glycyrrhiza uralensis (NERG) was analyzed by high‐performance liquid chromatography (HPLC). Antioxidant ability was determined by method of TPC and DPPH. Blood pressure was monitored by using blood pressure meter. In the acute study, a single dose (2,000 mg/kg) was orally administered to mice. In the subchronic study, mice were treated with extract at doses (50, 100, 500, and 1,000 mg/kg) for 120 days. Significantly difference was not shown at blood pressure, hematological, and biochemical parameters, and histopathology on mice. The results suggested that at acute and subchronic toxicity, each levels of nonpolar licorice extract administration in experiments did not cause toxicity effects or death on mice.
In this study, we first investigated the influence of Melandrium firmum Rohrbach (MF) on the accumulation of lipid content in 3T3‐L1 cells and in vitro results showed that MF extraction suppressed the differentiation of 3T3‐L1 pre‐adipocytes in a concentration‐dependent manner without showing cytotoxicity. Hence, we studied the effects of MF on preventing obesity in C57BL/6N mice. The results showed that MF decreased food efficiency ratio, body weight, epididymal adipose and hepatic tissue weight, hepatic lipid metabolites, and triacylglycerol and cholesterol serum levels, when compared with the high‐fat diet group. Moreover, MF significantly inhibited the expression of genes related to adipogenesis, such as PPAR‐γ, C/EBP‐α, and aP2, and those related to lipogenesis, such as SREBP‐1c, FAS, SCD‐1, and CD36 in epididymal adipose and liver tissues. These anti‐adipogenic and anti‐lipogenic effects of MF suggest that it could be used as a food including potential functional ingredient to prevent high‐fat diet‐induced obesity.
Asthma is a pulmonary disease induced by the inhalation of aeroallergens and subsequent inappropriate immune responses. Camellia sinensis (L.) Kuntze has been evaluated as an effective antioxidant supplement produced from bioactive compounds, including flavonoids. In this study, we aimed to determine the effects of Camellia sinensis (L.) Kuntze extract (CE) on ovalbumin-induced allergic asthma. The components of CE were analyzed using high-performance liquid chromatography (HPLC) chromatogram patterns, and asthmatic animal models were induced via ovalbumin treatment. The antioxidant and anti-inflammatory effects of CE were evaluated using 2,2-diphenyl-1-picryl-hydrazyl-hydrate (DPPH), 2,2′-azino-bis-3-ethylbenzthiazoline-6-sulphonic acid (ABTS), and nitric oxide (NO) assays. Seven compounds were detected in the CE chromatogram. In the ovalbumin-induced mouse model, CE treatment significantly decreased the inflammation index in the lung tissue. CE also significantly decreased eosinophilia and the production of inflammatory cytokines and OVA-specific IgE in animals with asthma. Collectively, our results indicate that CE has anti-inflammatory and antioxidant activities, and that CE treatment suppresses asthmatic progression, including mucin accumulation, inflammation, and OVA-specific IgE production.
Cachexia is a devastating fat tissue and muscle wasting syndrome associated with every major chronic illness, including cancer, chronic obstructive pulmonary disease, kidney disease, AIDS, and heart failure. Despite two decades of intense research, cachexia remains under-recognized by oncologists. While numerous drug candidates have been proposed for cachexia treatment, none have achieved clinical success. Only a few drugs are approved by the FDA for cachexia therapy, but a very low success rate is observed among patients. Currently, the identification of drugs from herbal medicines is a frontier research area for many diseases. In this milieu, network pharmacology, transcriptomics, cheminformatics, and molecular docking approaches were used to identify potential bioactive compounds from herbal medicines for the treatment of cancer-related cachexia. The network pharmacology approach is used to select the 32 unique genes from 238 genes involved in cachexia-related pathways, which are targeted by 34 phytocompounds identified from 12 different herbal medicines used for the treatment of muscle wasting in many countries. Gene expression profiling and functional enrichment analysis are applied to decipher the role of unique genes in cancer-associated cachexia pathways. In addition, the pharmacological properties and molecular interactions of the phytocompounds were analyzed to find the target compounds for cachexia therapy. Altogether, combined omics and network pharmacology approaches were used in the current study to untangle the complex prognostic genes involved in cachexia and phytocompounds with anti-cachectic efficacy. However, further functional and experimental validations are required to confirm the efficacy of these phytocompounds as commercial drug candidates for cancer-associated cachexia.
26 January 2024 in Molecular & Cellular Toxicology